Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

January 18, 2002

Slides

Pravastatin-Aspirin

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Introduction Pravastatin-Aspiring, Fred T Fiedorek, MD, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute, Bristol-Myers Squibb  ppt  htm

Pravastatin-Aspirin Combination, Rene Belder, MD, Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute  ppt   htm

Efficacy of the Combination:  Meta-Analyses, Donald A Berry, PhD, Frank T. McGraw Memorial Chair of Cancer Research, University of Texas, MD Anderson Cancer Center   ppt   htm

Pravastatin-Aspirin Combination: The Medical Need, Thomas A Pearson, MD, PhD, Albert D Kaiser Professor of Community & Preventive Medicine, University of Rochester, School of Medicine  ppt  htm